Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
August 08 2018 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will present a corporate overview
at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday,
August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hotel in New
York, NY.
A webcast of the presentation will be available in the Investors
section of the Company’s website, www.catabasis.com, and will be
archived for 30 days following the presentation.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy. The
global Phase 3 POLARIS DMD trial is expected to initiate in the
second half of 2018. For more information on edasalonexent and our
Phase 3 POLARIS DMD trial, please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180808005022/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024